Get the latest news, insights, and market updates on MRK (Merck & Co., Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Nine Drugmakers Strike Deals With Trump, With More to Come
The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office. Dec 19, 2025 - $MRK
Jim Cramer Explains How Market Rotation Boosted Companies Like Johnson & Johnson
Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the […] Dec 19, 2025 - $MRK
Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes
ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri Dec 19, 2025 - $MRK
Top Research Reports for NVIDIA, Netflix & Merck
New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut. Dec 19, 2025 - $MRK
Three Prominent Dividend Stocks To Consider
As the U.S. stock market experiences a resurgence, with major indexes like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities across various sectors. In this dynamic environment, dividend stocks stand out as a compelling option for those seeking consistent income streams alongside potential capital appreciation. Dec 19, 2025 - $MRK
Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has bee Dec 19, 2025 - $MRK
Novo files for CagriSema approval; Merck and Pfizer’s trial win
Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study. Dec 19, 2025 - $MRK
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple